Latest news
Gilead reports strong Q2 driven by HIV portfolio - EMJEMJ · Thu, 06 Aug 2026 16:39:36 GMTGilead lifts sales outlook on strong Q2 HIV growth despite acquisition-related loss - The Pharma LetterThe Pharma Letter · Wed, 05 Aug 2026 13:02:31 GMTGilead's Steady Long-Term Growth Prospects in HIV and Expansion in Oncology Support a Wide Moat - MorningstarMorningstar · Wed, 05 Aug 2026 05:06:10 GMTGILD: HIV and PrEP sales surged, driving raised guidance and strong growth across core portfolios - TradingViewTradingView · Tue, 04 Aug 2026 10:11:33 GMTMRK: Once-weekly and monthly oral HIV regimens show strong efficacy, targeting $5B+ by mid-2030s - TradingViewTradingView · Mon, 03 Aug 2026 14:58:41 GMTMRK: Once-weekly oral HIV regimens show high efficacy, safety, and strong patient preference - TradingViewTradingView · Mon, 03 Aug 2026 12:32:31 GMTNACA urges stronger domestic funding to sustain Nigeria’s HIV fight - Punch NewspapersPunch Newspapers · Thu, 30 Jul 2026 07:00:00 GMT[AIDS 2026] [Press release] ViiV Healthcare: New European, community co-created survey reveals strong interest in long-acting HIV treatment options but reported in-clinic conversations lag behind - European AIDS Treatment GroupEuropean AIDS Treatment Group · Thu, 30 Jul 2026 00:33:47 GMT